volume 53, issue 1, P186-192 2009
DOI: 10.1128/aac.00333-08
View full text
|
Sign up to set email alerts
|
Share

Abstract: Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for the treatment of and prophylaxis against influenza. In this paper, the new potent NA inhibitor R-125489 is reported for the first time. R-125489 inhibited the NA activities of various type A and B influenza viruses, including subtypes N1 to N9 and oseltamivir-resistant viruses. The survival effect of R-125489 was shown to be similar to that of zanamivir when administered intranasally in a mouse i…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

4
159
0
3

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals